Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 10/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.51 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.50 |
| ▸ | SCD | O00767 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5897429 | 0.87 | CHEK2 (0.70) | CHEK2KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL1381456 | 0.86 | CHEK2 (0.85) | CHEK2 | |
| SCHEMBL5177605 | 0.82 | CHEK2 (0.68) | CHEK2KMT2A | |
| SCHEMBL10086452 | 0.78 | CHEK2 (0.62) | CHEK2KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL5898191 | 0.77 | CHEK2 (0.74) | CHEK2KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL23388266 | 0.76 | VCAM1 (0.53) | CHEK2KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL5897634 | 0.76 | CHEK2 (0.68) | CHEK2KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL10656533 | 0.74 | KDR (0.56) | CHEK2KMT2ALMNA | |
| SCHEMBL4191143 | 0.74 | DGAT1 (0.74) | CHEK2KMT2A | |
| SCHEMBL3916733 | 0.74 | CHEK2 (0.71) | CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687639-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-30 | — | — | US | disclosed |
| US-20060252793-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | BW CONVERTING AB (SE) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252793-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | CDKN1A, DDB1, TMBIM6 | CHEK2 14/4885KDM4E 3815/4885ALDH1A1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.